UK Markets open in 6 hrs 25 mins

Hutchison China MediTech Limited (HCM.L)

LSE - LSE Delayed price. Currency in GBp (0.01 GBP)
Add to watchlist
244.00+12.50 (+5.40%)
At close: 05:05PM GMT
Full screen
Previous close231.50
Bid0.00 x 0
Ask243.00 x 0
Day's range0.00 - 0.00
52-week range
Avg. volume147,616
Market cap2.11B
Beta (5Y monthly)0.90
PE ratio (TTM)N/A
EPS (TTM)-13.00
Earnings date28 Feb 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4.40
  • Globe Newswire

    HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China

    HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 14, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM, HKEX:13) today announces that, further to its announcement on January 23, 2023 and following the completion of customary closing conditions including antitrust regulatory reviews, the exclusive license agreement with a subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502, NYSE:TAK) to further the global development, commercialization and manufac

  • Globe Newswire

    HUTCHMED Confirms No Assets Held at Silicon Valley Bank

    HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., March 13, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM:​HCM, HKEX:​13) today confirms that it does not have any exposure to Silicon Valley Bank (“SVB”) or Silicon Valley Bank UK Limited (“SVBUK”). The Company does not hold any cash deposits or securities with SVB or SVBUK. About HUTCHMED HUTCHMED (Nasdaq/AIM:​HCM; HKEX:​13) is an innovative, commercial-stage, biopharmaceutical company. It is comm

  • Globe Newswire

    HUTCHMED Reports 2022 Full Year Results and Provides Business Updates

    Landmark licensing deal with Takeda for fruquintinib outside of China, bringing HUTCHMED up to US$1.13 billion, plus royalties, and demonstrating execution of the new global strategy Record Full Year 2022 oncology/immunology revenues driven by significant increase in China in-market sales of ELUNATE®, SULANDA® and ORPATHYS® alongside clinical and strategic progress Company to Host Annual Results Call & Webcast Today at 9 p.m. HKT / 1 p.m. GMT / 8 a.m. EST HONG KONG, SHANGHAI, China and FLORHAM P